RecruitingPhase 1NCT06980116

Dose Determining Study of EXS73565 in Participants With Relapsed or Refractory B-Cell Malignancies

A Phase 1 Open-label, Multicenter, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of EXS73565 in Participants With Relapsed or Refractory B-cell Malignancies

Sponsor

Exscientia AI Ltd., a wholly owned subsidiary of Recursion Pharmaceuticals, Inc.

Enrollment

85 participants

Start Date

Mar 31, 2025

Study Type

INTERVENTIONAL

Conditions

Diffuse Large B-Cell Lymphoma (DLBCL)Follicular Lymphoma ( FL)Mantle Cell Lymphoma (MCL)Marginal Zone Lymphoma (MZL)Relapsed or Refractory B-cell Malignancies Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)Waldenstrom's Macroglobulinemia (WM)

Summary

The purpose of this study is to characterize the safety, tolerability, pharmacokinetics, pharmacodynamics, and preliminary antitumor activity of EXS73565 administered orally as a single agent in participants with relapsed/refractory B-cell malignancies.

Eligibility

Min Age: 18 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called EXS73565 for people with chronic lymphocytic leukemia/small lymphocytic lymphoma (cll/sll), diffuse large b-cell lymphoma (dlbcl), and other related conditions. The study is currently recruiting participants at 9 locations. People eligible for this study include aged 18 Years and older.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGEXS73565

EXS73565 oral administration

Locations(17)

LLC ARENSIA Exploratory Medicine

Tbilisi, Georgia

Laiko General Hospital of Athens

Athens, Greece

University General Hospital of Patras

Pátrai, Greece

General Hosptial of Thessaloniko G. Papanikolaou

Thessaloniki, Greece

IMSP Institute of Oncology, ARENSIA Exploratory Medicine

Chisinau, Moldova

Pratia MCM

Krakow, Poland

Wojewodzkie Wielospecjalistyczne Centrum Onkologii i Traumatologi (Copernicus Memorial Hospital)

Lodz, Poland

Uniwersytecki Szpital Kliniczny Nr 4 w Lublinie

Lublin, Poland

Aidport Sp. z o.o. - PPDS

Skórzewo, Poland

Hospital Beata Maria Ana

Madrid, Spain

MD Anderson Cancer Center Madrid

Madrid, Spain

Hospital Fundación Jiménez Diaz

Madrid, Spain

Hospital Universitario HM Sanchinarro

Madrid, Spain

Clinica Universidad de Navarra

Pamplona, Spain

Medical Center of LLC ARENSIA Exploratory Medicine

Kyiv, Ukraine

St James's University Hospital

Leeds, United Kingdom

University Hospitals Plymouth NHS Trust (Derriford Hospital)

Plymouth, United Kingdom

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06980116

Related Trials

A Study to Compare How Well Odronextamab Combined With Chemotherapy Works and How Safe it is Against Rituximab Combined With Chemotherapy, in Adult Patients With Previously Untreated Diffuse Large B-cell Lymphoma

NCT06091865168 locations

Proton Therapy for Mediastinal Lymphoma (PROMLY)

NCT07817641

Surovatamig (AZD0486) as Monotherapy in Participants With Relapsed/Refractory (R/R) B-cell NHL

NCT0652679394 locations

A Trial to Learn if Odronextamab is Safe and Well-Tolerated and How Well it Works Compared to Rituximab Combined With Different Types of Chemotherapy for Adult Participants With Previously Untreated Follicular Lymphoma

NCT06091254190 locations

Lifestyles Implemented-Survivorship Care Plan In Lymphoma Survivors

NCT0593408440 locations